Diaceutics (LON:DXRX) Trading 0.7% Higher – Here’s What Happened

Diaceutics PLC (LON:DXRX – Get Free Report) rose 0.7% during mid-day trading on Thursday . The stock traded as high as GBX 146 and last traded at GBX 146. 67,335 shares were traded during trading, a decline of 66% from the average daily volume of 195,402 shares. The stock had previously closed at GBX 145.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group raised their price objective on shares of Diaceutics from GBX 215 to GBX 216 and gave the stock a “buy” rating in a report on Thursday, June 4th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Diaceutics presently has a consensus rating of “Buy” and a consensus target price of GBX 205.33.

Get Diaceutics alerts:

Read Our Latest Stock Analysis on DXRX

Diaceutics Trading Up 0.7%

The stock’s fifty day moving average price is GBX 157.96 and its 200 day moving average price is GBX 152.55. The stock has a market cap of £123.56 million, a P/E ratio of 1,327.27 and a beta of 0.89. The company has a current ratio of 3.43, a quick ratio of 9.92 and a debt-to-equity ratio of 2.85.

Diaceutics (LON:DXRX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 26th. The company reported GBX 11 earnings per share (EPS) for the quarter. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%. The company had revenue of GBX 3,844 million during the quarter. Equities research analysts expect that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

Diaceutics Company Profile

(Get Free Report)

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.

Recommended Stories

• Five stocks we like better than Diaceutics
• MDA Space Targets US Defense Market With $620M Acquisition
• Carnival’s Second Quarter: Is the Stock Still Complicated?
• Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
• Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal

Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.